A randomized controlled trial of integrated TCM and Western Medicine in the treatment of severe novel coronavirus pneumonia (COVID-19)

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000029438

Enrollment

Unknown

Registered

2020-02-01

Start date

2020-02-04

Completion date

Unknown

Last updated

2020-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

novel coronavirus pneumonia (COVID-19)

Interventions

control group:western medical therapies

Experimental group:Conventional medicine + TCM

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Pneumonia patients diagnosed as new coronavirus infection; 2) The type of pneumonia was judged as severe and critical; 3) Informed consent.

Exclusion criteria

Exclusion criteria: 1) patients were judged not suitable to participate in the study; 2) patients were not suitable to use Chinese patent medicine.

Design outcomes

Primary

Measure	Time frame
CURB-65;PSI score;Mechanical ventilation time;Length of stay in hospital;	—

Secondary

Measure	Time frame
Antipyretic time;Pulmonary function;mortality and recovery rate;rate of multiple organ dysfunction;Time of virus turning negative;Inflammation index;Adverse events;	—

Countries

China

Contacts

Public ContactLIU QINGQUAN, MIAO QING, ZHANG BOLI

Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University/Beijing institute of Traditional Chinese Medicine

ZJHTCM@FOXMAIL.COM+86 13902020873

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026